Merck & Co Inc logo

MRK

Merck & Co Inc

$90.98

Earnings Summary

Revenue
$14593Mn
Net Profits
$3944Mn
Net Profit Margins
27.03%
PE Ratio
13.83

Highlights

Revenue:

Merck & Co Inc’s revenue jumped 27.99% since last year same period to $14593Mn in the Q2 2022. On a quarterly growth basis, Merck & Co Inc has generated -8.23% fall in its revenue since last 3-months.

Net Profits:

Merck & Co Inc’s net profit jumped 155.28% since last year same period to $3944Mn in the Q2 2022. On a quarterly growth basis, Merck & Co Inc has generated -8.49% fall in its net profits since last 3-months.

Net Profit Margins:

Merck & Co Inc’s net profit margin jumped 99.45% since last year same period to 27.03% in the Q2 2022. On a quarterly growth basis, Merck & Co Inc has generated -0.29% fall in its net profit margins since last 3-months.

PE Ratio:

Merck & Co Inc’s price-to-earnings ratio after this Q2 2022 earnings stands at 13.83.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Merck & Co Inc post its latest quarter earnings

EPS Estimate Current Quarter
1.86
EPS Estimate Current Year
1.86

Highlights

EPS Estimate Current Quarter:

Merck & Co Inc’s earning per share (EPS) estimates for the current quarter stand at 1.86 - a 9.41% jump from last quarter’s estimates.

EPS Estimate Current Year:

Merck & Co Inc’s earning per share (EPS) estimates for the current year stand at 1.86.

Key Ratios

Key ratios of the Merck & Co Inc post its Q2 2022 earnings

Earning Per Share (EPS)
1.87
Return on Assets (ROA)
0.13
Return on Equity (ROE)
0.43
Dividend Per Share (DPS)
2.68

Highlights

Earning Per Share (EPS):

Merck & Co Inc’s earning per share (EPS) jumped 42.75% since last year same period to 1.87 in the Q2 2022. This indicates that the Merck & Co Inc has generated 42.75% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Merck & Co Inc’s return on assets (ROA) stands at 0.13.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Merck & Co Inc’s return on equity (ROE) stands at 0.43.

Dividend Per Share (DPS):

Merck & Co Inc declared 2.68 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
1.83
2.14
16.94%
2022-06-30
1.7
1.87
10%

Company Information

Merck & Co., Inc. is an American multinational pharmaceutical company. The corporation conducts business outside of the United States and Canada under Merck Sharp & Dohme (MSD). It was founded as an American subsidiary of the German pharmaceutical company Merck & Co. in 1891. The company was given this name in honour of the Merck family. Merck acquired the Livogen trademark from Glaxo India for Rs 8 crore in 2000 - well over the market value. According to the company, Rofecoxib will be distributed in the Philippines via a co-marketing arrangement with the local pharmaceutical business Kopran. When Biochem Pharmaceutical Industries Ltd purchased Taloja in 2004, the firm spent a total of Rs 100 million, making it the most costly acquisition the company had made then. On March 27, 2002, a decision was made to rename the company from E Merck (India) Ltd to Merck Ltd, and the company was officially constituted on that day. This increased the firm's capacity for the manufacturing of Bulk Drugs by 33 tonnes in 2006, increasing the company's overall production capacity to 351 tonnes. In 2020, the pharmaceutical business will have six blockbuster medications or products with more than $1 billion in revenue. An antibody used to treat cancer is Keytruda, estimated to make $14.3 billion this year. Varivax is supposed to make $3.9 billion each, and Gardasil will make $1.4 billion each. Currently Merck & Co Inc has a market cap of $226.28 Billion. It has a P.E ratio of 15.55. The shares of Merck & Co Inc are trading at $88.0. .

Organisation
Merck & Co Inc
Headquarters
Kenilworth, New Jersey, US
Employees
2.02K
Industry
Health Technology
CEO
Kenneth Frazier